Search results for "Integrase"

showing 10 items of 49 documents

Mast cells as rapid innate sensors of cytomegalovirus by TLR3/TRIF signaling-dependent and -independent mechanisms

2014

The succinct metaphor, ‘the immune system's loaded gun', has been used to describe the role of mast cells (MCs) due to their storage of a wide range of potent pro-inflammatory and antimicrobial mediators in secretory granules that can be released almost instantly on demand to fight invaders. Located at host–environment boundaries and equipped with an arsenal of pattern recognition receptors, MCs are destined to be rapid innate sensors of pathogens penetrating endothelial and epithelial surfaces. Although the importance of MCs in antimicrobial and antiparasitic defense has long been appreciated, their role in raising the alarm against viral infections has been noted only recently. Work on cy…

MaleChemokineImmunologyCytomegalovirusBiologyCD8-Positive T-LymphocytesCCL5MiceImmune systemImmunology and AllergyCytotoxic T cellAnimalsMast CellsMice KnockoutIntegrasesMacrophagesDegranulationPattern recognition receptorhumanitiesToll-Like Receptor 3Killer Cells NaturalMice Inbred C57BLAdaptor Proteins Vesicular TransportInfectious DiseasesTRIFImmunologyTLR3Cytomegalovirus Infectionsbiology.proteinFemaleResearch Article
researchProduct

Postnatal Deletion of Numb/Numblike Reveals Repair and Remodeling Capacity in the Subventricular Neurogenic Niche

2006

Neural stem cells are retained in the postnatal subventricular zone (SVZ), a specialized neurogenic niche with unique cytoarchitecture and cell-cell contacts. Although the SVZ stem cells continuously regenerate, how they and the niche respond to local changes is unclear. Here we generated nestin-creERtm transgenic mice with inducible Cre recombinase in the SVZ, and removed Numb/Numblike, key regulators of embryonic neurogenesis from postnatal SVZ progenitors and ependymal cells. This resulted in severe damage to brain lateral ventricle integrity, and identified previously unknown roles for Numb/Numblike in regulating ependymal wall integrity and SVZ neuroblast survival. Surprisingly, the ve…

MaleEpendymal Cellanimal diseasesSubventricular zoneMice TransgenicNerve Tissue ProteinsCell CommunicationBiologyArticleGeneral Biochemistry Genetics and Molecular BiologyNestinMice03 medical and health sciences0302 clinical medicineIntermediate Filament ProteinsNeuroblastEpendymaLateral VentriclesmedicineAnimals030304 developmental biologyNeuronsGenetics0303 health sciencesIntegrasesBiochemistry Genetics and Molecular Biology(all)Stem CellsNeurogenesisIntracellular Signaling Peptides and ProteinsBrainMembrane ProteinsEmbryonic stem cellNeural stem cellCell biologyMice Inbred C57BLmedicine.anatomical_structureAnimals Newbornnervous systemNUMBFemaleStem cellGene Deletion030217 neurology & neurosurgeryCell
researchProduct

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2016

Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.

MaleHuman immunodeficiency virus 1EtravirineRNA directed DNA polymerase inhibitordarunavirHIV InfectionsSettore MED/42 - Igiene Generale E Applicata:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Salud públicageneticsInhibidores de proteasas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]atazanavirmedia_commontransmission:Geographicals::Geographic Locations::Europe [Medical Subject Headings]3. Good healthmicrobial sensitivity testpriority journalEurope ; HIV-1 ; antiretroviral therapy ; drug resistance ; transmissionHIV/AIDSlamivudineReverse Transcriptase Inhibitors/pharmacologyanti human immunodeficiency virus agentDrugMicrobiology (medical)medicine.medical_specialtyantiviral susceptibility:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]media_common.quotation_subjectantiretroviral therapy030106 microbiologyHIV Infections/drug therapy:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]Microbial Sensitivity TestsRILPIVIRINEArticleEFAVIRENZ03 medical and health sciencestransmitted drug resistanceSDG 3 - Good Health and Well-beingHumansTransmissionhuman:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]REVERSE-TRANSCRIPTASE INHIBITORSRilpivirinaINTEGRASEMUTATIONSabacavirmajor clinical studyVirologyInfecciones por VIHRegimenAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Medicine (all); Microbiology (medical); Infectious DiseaseschemistryDrug resistance:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]MutationHIV-10301 basic medicinenevirapineDrug resistanceCommunicable diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]chemistry.chemical_compoundantiviral therapyINFECTIONMedicine and Health SciencesPrevalence:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]ViralNon-U.S. Gov'tReverse-transcriptase inhibitorantiretrovirus agentResearch Support Non-U.S. Gov'tMedicine (all)Human immunodeficiency virus infected patientMiddle AgedvirologyPREVALENCEAntiretroviral therapyEncuestas y CuestionariosANTIRETROVIRAL TREATMENTEuropeInfectious DiseasesHIV-1/drug effectsHIV Protease Inhibitors/pharmacologyRilpivirineReverse Transcriptase Inhibitors:Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]FemaleHIV drug resistancemedicine.drugAdultHuman immunodeficiency virus proteinase inhibitor:Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]EfavirenzAnti-HIV AgentsResearch SupportResistencia a medicamentosSettore MED/17 - MALATTIE INFETTIVEantiviral resistanceInternal medicineAnti-HIV Agents/pharmacologyDrug Resistance ViralJournal Articlemedicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]abacavir plus lamivudineEuropa (Continente)Antiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Adult; Anti-HIV Agents; Drug Resistance Viral; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Microbiology (medical); Infectious DiseasesemtricitabinenonhumanIntervalos de confianzadrug resistanceMutaciónAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmissionbusiness.industryHIVpredictionInhibidores de la transcriptasa inversaHIV Protease InhibitorsHuman immunodeficiency virus 1 infectiontenofovirINDIVIDUALSDrug Resistance Viral/geneticsBenzoxazinasETRAVIRINEdrug effects3121 General medicine internal medicine and other clinical medicinePrevalenciabusiness
researchProduct

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort

2017

International audience; Background & aims: There is little data available on the use of new oral direct-acting antiviral (DAA) regimens to treat human immunodeficiency virus and hepatitis C virus (HIV/HCV) co-infected patients in real-life settings. Here, the efficacy and safety of all-oral DAA-based regimens in HIV/HCV-co-infected patients enrolled in the French nationwide ANRS CO13 HEPAVIH observational cohort are reported.Methods: HIV/HCV-co-infected patients enrolled in the ANRS CO13 HEPAVIH observational cohort were included if they began an all-oral DAA-based regimen before 1st May 2015 (12-week regimens) or 1st February 2015 (24-week regimens). Treatment success (SVR12) was defined b…

Malemedicine.medical_specialtyHepatitis C virus[SDV]Life Sciences [q-bio]Integrase inhibitorHIV Infectionsmedicine.disease_causeAntiviral AgentsHIV/HCV co-infectionCohort Studies03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineparasitic diseasesmedicineHumans030212 general & internal medicineAdverse effectHepatologyReverse-transcriptase inhibitorbusiness.industryCoinfectionRibavirinvirus diseasesHepatitis C ChronicMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences3. Good healthRegimenSustained virological responseLogistic ModelschemistryImmunologyCohort030211 gastroenterology & hepatologyFemaleAll-oral DAAbusinessCohort studymedicine.drug
researchProduct

COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.

2020

ABSTRACT Background Little evidence on COVID‐19 in people living with HIV (PLWH) is currently available. Material and Methods We reported clinical and viro‐immunological data of all HIV‐positive patients admitted to our centre with COVID‐19 from March 1 to May 12,2020. Results Overall, five patients were included: all were virologically‐suppressed on antiretroviral therapy and CD4+ count was >350 cell/mm3 in all but two patients. Although all patients had evidence of pneumonia on admission, only one developed respiratory failure. SARS‐CoV‐2‐RNA was never detected from nasopharyngeal swabs in two patients, whereas, in the others, viral clearance occurred within a maximum of 43 days. IgG prod…

Malemedicine.medical_treatmentHIV InfectionsAntibodies ViralSeverity of Illness IndexImmunoglobulin GPiperazinesimmune responseSARS‐CoV‐20302 clinical medicine030212 general & internal medicinebiologyCoinfectionImmunosuppressionMiddle AgedInfectious DiseasesAnti-Retroviral AgentsCytokinesRNA ViralReverse Transcriptase Inhibitors030211 gastroenterology & hepatologyFemaleAntibodyHeterocyclic Compounds 3-RingRiskPyridonesShort CommunicationShort CommunicationsTransgender PersonsProinflammatory cytokine03 medical and health sciencesImmune systemCOVID‐19VirologySeverity of illnessOxazinesmedicineHumansHIV Integrase InhibitorsTenofovirbusiness.industrySARS-CoV-2medicine.diseaseHIV infectionVirologyAntibodies NeutralizingCD4 Lymphocyte CountImmunity HumoralCOVID-19 Drug TreatmentPneumoniaRespiratory failureImmunologybiology.proteinbusinessJournal of medical virology
researchProduct

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.

2014

Objectives Growing evidence associates the non-nucleoside reverse transcriptase inhibitor efavirenz with several adverse events. Newer antiretrovirals, such as the integrase inhibitor raltegravir, the non-nucleoside reverse transcriptase inhibitor rilpivirine and the protease inhibitor darunavir, claim to have a better toxicological profile than efavirenz while producing similar levels of efficacy and virological suppression. The objective of this study was to determine the in vitro toxicological profile of these three new antiretrovirals by evaluating their effects on the mitochondrial and cellular parameters altered by efavirenz in hepatocytes and neurons. Methods Hep3B cells and primary …

Microbiology (medical)CyclopropanesEfavirenzAnti-HIV AgentsIntegrase inhibitorBiologyMitochondrionPharmacologychemistry.chemical_compoundCell Line TumorRaltegravir PotassiumDrug Resistance ViralNitrilesmedicineAnimalsHumansPharmacology (medical)DarunavirCells CulturedDarunavirPharmacologyNeuronsSulfonamidesReverse-transcriptase inhibitorRilpivirinemedicine.diseaseRaltegravirPyrrolidinonesBenzoxazinesMitochondriaRatsMitochondrial toxicityInfectious DiseasesPyrimidineschemistryRilpivirineAlkynesHepatocytesReverse Transcriptase Inhibitorsmedicine.drugThe Journal of antimicrobial chemotherapy
researchProduct

Dissemination of CTX-M-Producing Escherichia coli in Freshwater Fishes From a French Watershed (Burgundy)

2019

International audience; The burden of extended-spectrum beta-lactamases producing Escherichia coli (ESBL-Ec), has increased over several decades. Freshwater ecosystems are suspected to play an important ecological and evolutionary role in driving the dissemination of antimicrobial resistance. The aim of our study was to decipher the occurrence of ESBL-Ec in a small watershed (Ouche river, Burgundy, France), targeting environmental matrices and fishes. Among cefotaxime resistant E. coli (ctxR Ec) isolates, we detected and characterized 36 ESBL-Ec from water, biofilm and fish guts. ctxR Ec and ESBL-Ec were found in samples from sites near the first small town, located downstream from the wate…

Microbiology (medical)Veterinary medicineCefotaximeESBL producing Escherichia coliantibiotic resistance[SDV]Life Sciences [q-bio]lcsh:QR1-502MLST E. colimedicine.disease_causeFreshwater ecosystemMicrobiologylcsh:Microbiologyclass 1 integron-integrase03 medical and health sciencesAntibiotic resistanceblaCTX–Mfreshwater;ESBL producing Escherichia coli;bla(CTX-M);class 1 integron-integrase;antibiotic resistance;fish;MLST E. colimedicine[SDV.BV]Life Sciences [q-bio]/Vegetal Biology14. Life underwaterbla(CTX-M)freshwaterEffluentEscherichia coliComputingMilieux_MISCELLANEOUS030304 developmental biologyOriginal Researchfish0303 health sciencesbiology030306 microbiologybiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycoses6. Clean water13. Climate action[SDE]Environmental SciencesMultilocus sequence typingbla CTX–MOmnivoreBacteriamedicine.drugFrontiers in Microbiology
researchProduct

A Quantum Mechanic/Molecular Mechanic Study of the Wild-Type and N155S Mutant HIV-1 Integrase Complexed with Diketo Acid

2008

Integrase (IN) is one of the three human immunodeficiency virus type 1 (HIV-1) enzymes essential for effective viral replication. Recently, mutation studies have been reported that have shown that a certain degree of viral resistance to diketo acids (DKAs) appears when some amino acid residues of the IN active site are mutated. Mutations represent a fascinating experimental challenge, and we invite theoretical simulations for the disclosure of still unexplored features of enzyme reactions. The aim of this work is to understand the molecular mechanisms of HIV-1 IN drug resistance, which will be useful for designing anti-HIV inhibitors with unique resistance profiles. In this study, we use mo…

Models MolecularProtein ConformationStereochemistryBiophysicsIntegrase inhibitorIntegrase InhibitorsHIV IntegraseBiophysical Theory and ModelingMechanicsMolecular mechanicsProtein structureComputer SimulationMagnesiumTernary complexBinding SitesbiologyChemistryAminobutyratesWild typeActive siteLigand (biochemistry)PhenylbutyratesIntegraseModels ChemicalMultiprotein ComplexesMutagenesis Site-Directedbiology.proteinQuantum TheoryProtein BindingBiophysical Journal
researchProduct

Calculation of binding energy using BLYP/MM for the HIV-1 integrase complexed with the S-1360 and two analogues.

2007

Abstract Integrase (IN) is one of the three human immunodeficiency virus type 1 (HIV-1) enzymes essential for effective viral replication. S-1360 is a potent and selective inhibitor of HIV-1 IN. In this work, we have carried out molecular dynamics (MD) simulations using a hybrid Quantum Mechanics/Molecular Mechanics (QM/MM) approach, to determine the protein–ligand interaction energy for S-1360 and two analogues. Analysis of the MD trajectories reveals that the strongest protein–inhibitor interactions, observed in the three studied complexes, are established with Lys-159 residue and Mg 2+ cation. Calculations of binding energy using BLYP/MM level of theory reveal that there is a direct rela…

Molecular modelStereochemistryProtein ConformationClinical BiochemistryBinding energyPharmaceutical ScienceHIV IntegraseCrystallography X-RayBiochemistryMolecular mechanicsMolecular dynamicsPropaneStructure-Activity RelationshipDrug DiscoveryHumansMagnesiumPyrrolesAmino Acid SequenceHIV Integrase InhibitorsFuransMolecular Biologychemistry.chemical_classificationbiologyChemistryLysineOrganic ChemistryActive siteInteraction energyTriazolesIntegraseEnzymeAmino Acid SubstitutionModels Chemicalbiology.proteinMolecular MedicineBioorganicmedicinal chemistry
researchProduct

Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.

2008

HIV-infected patients have a higher risk of developing cutaneous reactions than the general population, which has a significant impact on patients' current and future care options. The severity of cutaneous adverse reactions varies greatly, and some may be difficult to manage. HIV-infected patients just at the beginning of antiretroviral treatment can frequently show a wide variety of adverse drug effects such as drug rashes, hyperpigmentation, hair loss, hypersensitivity reactions, injection site reaction, urticarial reaction, erythema multiforme, toxic epidermal necrolysis or Stevens-Johnson syndrome. The early detection and treatment of cutaneous adverse drug reactions, plus identificati…

PharmacologyMicrobiology (medical)Enfuvirtidebusiness.industryAnti-HIV AgentsEtravirineIntegrase inhibitorHIV Infectionsmedicine.diseaseRaltegravirSkin Diseaseschemistry.chemical_compoundInfectious DiseaseschemistryInjection site reactionImmunologymedicineHumansPharmacology (medical)Protease inhibitor (pharmacology)businessTipranavirmedicine.drugMaravirocThe Journal of antimicrobial chemotherapy
researchProduct